Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Connect Biopharma Holdings Limited - Ordinary Shares (NQ:CNTB)

2.500 -0.180 (-6.72%)
Streaming Delayed Price Updated: 3:09 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Connect Biopharma Holdings Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Tuesday's after hours session: top gainers and losers ↗
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Bullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma to Present at Two Upcoming Investor Conferences
From Connect Biopharma Holdings Limited
Via GlobeNewswire
David Szekeres, President of Connect Biopharma Holdings Limited (NASDAQ: CNTB), to Present at NobleCon20
Via Investor Brand Network
News headline image
Attovia Therapeutics Appoints Chief Financial Officer
Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer 
From Attovia Therapeutics, Inc.
Via GlobeNewswire
News headline image
Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Week In Review: EpimAb Sells T-Cell Engager In $635 Million Deal ↗
EpimAb Biotherapeutics sold global rights for a clinical-stage asset to Vignette Bio, a San Francisco startup, in a $635 million deal. Meanwhile, Shenzhen TargetRx raised $20 million by selling China... 
Via Talk Markets
News headline image
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
From Connect Biopharma Holdings Limited
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Week in Review: SystImmune Out-Licenses Global Rights for ADC to BMS in $8.4 Billion Deal ↗
SystImmune, the Seattle arm of Chengdu’s Biokin Pharma, out-licensed global rights (ex-China) for a bispecific ADC to Bristol Myers Squibb in a $8.4 billion agreement. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS